Skip to main content

Search Results

Displaying: 1 - 10 of 15 Results

Continuous directed evolution of aminoacyl-tRNA synthetases to alter amino acid specificity and enhance activity

DESCRIPTION Functions of various biotherapeutics can often be enhanced by modifying individual amino acid residues. However, the current approaches rely on existing natural amino acid chemistry. Approaches that provide new chemical “handles” will…

Investigators

  • David Liu

Evolution of Sequence-Defined Highly Functionalized Nucleic Acid Polymers

DESCRIPTION Template-directed synthesis of modified DNA sequences can provide a rich source of material for generating new therapies featuring modified nucleic acid polymers. The Liu lab has previously developed pioneering methods to generate…

Investigators

  • David Liu

Oral delivery of biologics

Biologics are used to treat a variety of chronic diseases including diabetes and arthritis. Not surprisingly, they command a large share of the therapeutics market. Moreover, a large number of therapeutic proteins are currently in clinical…

Investigators

  • Samir Mitragotri

aP2 knock-out mice

AP2 knock-out mutant mice were developed by Dr. Gokhan Hotamisligil at Harvard Medical School (Science. 1996 Nov 22;274(5291):1377-9). AP2, also known as Fatty Acid-Binding Protein 4 (FABP4), encodes the adipocyte FABP. It plays important roles in…

Investigators

  • Gokhan Hotamisligil

First in class substrate-selective Insulin Degrading Enzyme (IDE) inhibitors for treating Diabetes

First in class substrate-selective Insulin Degrading Enzyme (IDE) inhibitors for treating Diabetes. Professor David Liu and a multidisciplinary research team have recently discovered and optimized of a series of small molecules (<550 Da, IC50 = 1…

Investigators

  • David Liu
  • Juan Pablo Maianti

The next generation of cholesterol screening - A personalized diagnostic index for the improved assessment of cardiovascular risk using a novel method for the measurement of lipoprotein subtypes

OpportunityThis program offers the next generation of cholesterol screening. In 2013, 96 million visits to doctors' offices in the US included a cholesterol test.Problem/Unmet needCurrent practice of measuring total HDL level in serum does not…

Investigators

  • Frank Sacks

Potent OGT inhibitors for the treatment of cancer and diabetic complications

First-in-class and potent OGT inhibitors The Walker group has developed novel high throughput assays (HTS) and screened 200,000 compounds at the Institute for Chemistry and Cell Biology (ICCB) at Harvard Medical School, and identified several…

Investigators

  • Suzanne Walker Kahne
  • Michael Lazarus
  • Benjamin Gross

Animal model of diabetes and obesity

Mice with the JNK 1 and JNK2 genes knocked out were crossed with the obese mouse line (ob/ob) to create a mouse model of diabetes and obesity. These mice exhibit many of the hallmark metabolic pertubations characteristic in diabetes and obesity.

Investigators

  • Gokhan Hotamisligil
  • Michael Karin

Using (-)-indolactam V to induce differentiation of human and mouse embryonic stem cells into pancreatic lineage

• ILV can be used alone, or in combination with growth factors, to direct differentiation of ESCs into pancreatic specification. ILV is effective on human ESC lines and mouse ESC lines. • ILV is effective on human ESC lines HUES 2, 4 and 8. After 4…

Investigators

  • Douglas Melton
  • Shuibing Chen
  • Malgorzata Borowiak
  • Julia Fox
  • Stuart Schreiber
  • Lee Peng
  • Lee Rubin
  • Kelvin Lam
  • Lance Davidow

Methods of direct reprogramming: converting pancreatic exocrine cells to beta cells

Scientists in Doug Melton’s laboratory at Harvard University have succeeded in directly reprogramming fully differentiated exocrine cells into beta-cells in adult animals, using a combination of three transcription factors: Ngn3, Pdx1 and Mafa. The…

Investigators

  • Douglas Melton
  • Qiao Zhou

Page 1 of 2